Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

James Wassil Biography and Net Worth

COO of Vaxcyte

James Wassil M.B.A., M.S. is the Chief Operating Officer at Vaxcyte.

How old is James Wassil?: Mr. Wassil is currently 55 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on James Wassil's age.
How do I contact James Wassil?: The corporate mailing address for Mr. Wassil and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on James Wassil's contact information.
Has James Wassil been buying or selling shares of Vaxcyte?: James Wassil has not been actively trading shares of Vaxcyte during the past quarter. Learn More on James Wassil's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Mikhail Eydelman (SVP), Jeff Fairman (VP), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 33 times. They sold a total of 281,096 shares worth more than $16,832,337.62. The most recent insider tranaction occured on April, 23rd when CEO Grant Pickering sold 15,000 shares worth more than $928,800.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 4/23/2024.

James Wassil Insider Trading History at Vaxcyte

James Wassil Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $66.67

$65.81

$68.22

50 Day Range

MA: $66.57

$60.06

$81.05

2 Week Range

Now: $66.67

$44.20

$82.04

Volume

258,304 shs

Average Volume

810,180 shs

Market Capitalization

$7.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94